Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

AG Edwards Ups Pharmaceutical Resources to 'Buy'


AG Edwards upgraded Pharmaceutical Resources (PRX) to buy from hold.

Analyst Albert Rauch says Pharmaceutical Resources has been very successful in using partnerships and litigation to gain six months marketing exclusivity for its generic products. He notes it demonstrated an ability to maintain high share in competitive markets. He says the company also is developing higher margin products.

Rauch expects the drugmaker's generic version of top-selling antidepressant Paxil, which is just started shipping to U.S. customers, to drive dramatic earnings per share growth over the next 12 months. He thinks Pharmaceutical Resources is well-positioned for future growth, and notes it has 25 products awaiting FDA approval.

Rauch sees $3.59 2003 earnings per share, and $4.04 earnings per share in 2004. He has a $81 12-month target.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus